DALLAS, Dec. 13, 2004 (PRIMEZONE) -- TalkingStocks.com issued an update to our Profile Report on Biophan Technologies, Inc. (OTCBB:BIPH). The Profile Report is authored by Jeff Bishop, Senior Investment Analyst for TalkingStocks.com. Discussed in the Profile Report is the importance of MRI technology, the limitations with MRI Technology for patients with implants, and the newly issued "Anti-Antenna" patent which gives Biophan market dominance in MRI safety.
Biophan's focus on building its technological platform and to develop into the dominant leader in MRI-safe and image compatible product segment is beginning to become a reality. The recent award of patent rights on the "anti-antenna" technique is a step toward the company achieving its objectives. Biophan has been able to demonstrate its ability to build on its core competencies in nanotechnology and the enhancement of the safety and effectiveness of medical applications of MRI. Biophan is in discussions with a number of device makers for licensing and prospective deals converting their patent technologies into potential revenue streams. With a strong base of technological expertise in place, Biophan is gearing to expand into related areas of the medical marketplace where significant business growth is projected.
To view the complete Profile Report, visit:
http://talkingstocks.com/reports/BIPH_121304.php
Registration is free.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have a total of 101 U.S. patents issued, pending, or allowed. This total includes 22 issued U.S. patents, 11 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit http://www.biophan.com.
About TalkingStocks.com
TalkingStocks.com offers interviews with key executives from publicly traded company. TalkingStocks.com is owned by TalkingStocks.com, LLC. Our services include executive interviews, company profiles, investor calls and our "Ask The CEO" show.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Disclosure: As of the date of this release, TalkingStocks.com, LLC, and its affiliate Pentony Enterprises, LLC (StockGuru.com), have been compensated an aggregate total of $15,000. The company paid $9000 for coverage. Prior compensation of $6000 came from Trilogy Capital Partners, the investor relations firm for Biophan Technologies (BIPH). Neither TalkingStocks.com, LLC, nor Pentony Enterprises, LLC, are registered investment advisers or broker/dealers. TalkingStocks.com, LLC and Pentony Enterprises, LLC makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.